Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Circulation. 2002;106:2510-2513
doi: 10.1161/01.CIR.0000036743.07406.53
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gori, T.
Right arrow Articles by Parker, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gori, T.
Right arrow Articles by Parker, J. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Endothelium/vascular type/nitric oxide

(Circulation. 2002;106:2510.)
© 2002 American Heart Association, Inc.

Mini-Review

Nitrate Tolerance

A Unifying Hypothesis

Tommaso Gori, MD; John D. Parker, MD

From the Division of Cardiology, Department of Medicine, Mount Sinai and University Health Network Hospitals, University of Toronto, Toronto, Canada.

Correspondence to John D. Parker, MD, FRCP(C), Division of Cardiology, Department of Medicine, Mount Sinai Hospital, 600 University Ave, Suite 1609, Toronto, Ontario, Canada M5G 1X5. E-mail jdp{at}inforamp.net


Key Words: acetylcholine • nitroglycerin • endothelium • nitric oxide synthase • blood flow

The first part of this review provided a synopsis of the recent literature about superoxide anion (·O2-) production, endothelial dysfunction, and the neurohormonal activation that follow long-term administration of organic nitrates. In this issue of Circulation, we will try to integrate these observations with other separate, and, to a certain extent, antagonistic hypotheses that have been proposed for the development of nitrate tolerance.1–3 Hypotheses concerning the pathogenesis of tolerance have traditionally been grouped into 2 different categories. The "dispositional" or "metabolic" theory postulates that the effect of organic nitrates wanes during continuous use as the result of decreased biotransformation or decreased activity of the nitric oxide (NO) adjunct released in this process (end-organ tolerance). The "functional" theory emphasizes the importance of counterregulatory mechanisms that occur in response to nitrate therapy, including neurohormonal activation and plasma volume expansion. These mechanisms could counterbalance and overcome the effects of nitrates, a process that has been termed "pseudotolerance."3,4

Recent findings described in the first part of this article provide an opportunity to hypothesize explanations for a number of previous observations in the field of nitrate tolerance by applying increased ·O2- production as the underlying mechanism. In the following text, the evidence for this concept is reviewed, and a unifying hypothesis based on a self-promoting mechanism triggered by increased vascular ·O2- generation is proposed.

Plasma Volume Expansion During Nitrate Therapy

Several studies reported that nitrate therapy causes plasma volume expansion, as demonstrated by a decreased hematocrit during nitrate therapy both in healthy volunteers5 and patients with congestive heart failure or ischemic heart disease.6 This observation led to the hypothesis that increased circulating volume and, subsequently, filling pressures, would counteract the nitroglycerin (GTN)–induced decrease in preload, thus causing nitrate tolerance. Increased water retention and/or fluid shifts from the extravascular to the intravascular compartment have been proposed as mechanisms for these changes.6,7 The activation of the renin-angiotensin-aldosterone axis and the increased angiotensin II production during tolerance might mediate both processes. Furthermore, the recent demonstration that GTN treatment causes increased levels of isoprostanes,8 given their direct vasoconstrictor and antinatriuretic effects,9 provides an additional, redox-mediated explanation. Finally, changes in the redox state in the endothelial cellular milieu, and, in particular, changes in the availability of reduced thiol groups, might induce abnormalities in microvascular permeability.10 Despite these theories, a number of observations limit the importance of plasma volume expansion as a causal mechanism of tolerance, including: (1) the discrepancy in the time course of the two phenomena6; (2) the demonstration that tolerance can be induced in isolated vessels; and (3) the lack of preventive effect of diuretics.11,12 These observations suggest, however, that plasma volume expansion might be one of the effects induced, at least in part, by an increased oxygen free radical production.

Abnormalities in Organic Nitrate Biotransformation
Abnormalities in the biotransformation process through which the nitrate undergoes denitrification to yield NO or some NO adjunct(s) were proposed as a mechanism of tolerance almost 3 decades ago.13 Despite the existence of negative reports,14 new interest in this hypothesis has developed. The concept that nitrate biotransformation becomes impaired finds support in a number of studies demonstrating that tolerance is accompanied by reduced formation of the GTN metabolite 1,2 dinitrate.15,16 An impaired biotransformation of GTN and other nitrates, such as isosorbide mononitrate and dinitrate, would also help explain the finding that spontaneous NO donors, such as nitroprusside and other nonorganic NO donors, are subject to relatively lesser degrees of tolerance.17–20

Whether reduced biotransformation is a relevant mechanism of tolerance, and, most importantly, which enzymes are involved in the activation of GTN, will require further investigation. The microsomal cytochrome P450, glutathione transferases, NAD(P)H and xanthine oxidases, and, finally, given its cytochrome-like structure, nitric oxide synthase (NOS),21–25 have all been proposed. However, incubation with inhibitors of these enzymes blunted GTN responses to the same extent in tolerant and nontolerant vessels, demonstrating that tolerance is not associated with any decrease in their activity.24 To date, GTN biotransformation has been demonstrated to be inhibited by NO,26 but its redox sensitivity has not been formally investigated.

Decreased bioavailability of reduced thiols necessary for GTN biotransformation was originally identified by Needleman et al27 as the cause of tolerance. It now seems that free thiol groups are not a necessary substrate for NO release from GTN and that they are not depleted during nitrate exposure.28 However, oxidation of protein-bound thiols resulting from an alteration in cellular ·O2- bioavailability might compromise the function of different enzymes, including NOS29 and membrane enzymes,30 resulting in a free radical–mediated inhibition of GTN biotransformation in the setting of tolerance. Furthermore, multiple studies have demonstrated that changes in redox state or increased peroxynitrite production can impair the activity of heme proteins, such as cytochrome P450 and NOS,31,32 and can also inhibit glutathione S-transferases, another family of enzymes potentially involved in GTN biotransformation.33 Finally, Chen et al34 provided evidence that the mitochondrial aldehyde reductase is able to catalyze the production of nitrite and 1,2 glyceryl dinitrate through a process that seems to depend on reduced sulfhydryl groups. The subcellular location of this enzyme might make it particularly susceptible to oxidative changes, as high mitochondrial concentrations of NO inhibit the respiratory chain, thus inducing ·O2- generation.35 In sum, impaired GTN transformation might participate in the development of tolerance, although it cannot explain many of the abnormalities observed in this setting. Future research will have to formally address the ·O2--sensitivity of GTN biotransformation.

Abnormalities in NO Signal Transduction
A number of studies have suggested that prolonged exposure to nitrates might diminish not only the bioavailability but also the efficacy of their active metabolite NO.36–38 The GTN-released NO activates the enzyme-soluble guanylyl cyclase (sGC) in smooth muscle cells, thus increasing tissue levels of the second messenger cGMP, which, in turn, leads to the activation of a cGMP-dependent protein kinase (cGK) (Figure 1). This enzyme mediates vasorelaxation through the phosphorylation of different proteins involved in the regulation of intracellular Ca2+ levels. End-organ tolerance might be mediated by decreased activity of the sGC, increased activity of phosphodiesterases (PDE, the enzymes responsible for cellular cGMP catabolism), or decreased activity of the cGK, the final effector of the system. The former 2 mechanisms would reduce the bioavailability of the intracellular second messenger cGMP, whereas the latter would impair its effects. Modifications in the activity of these enzymes might explain the partial decrease in the responses to endothelium-dependent and other NO-dependent vasodilators.19,39,40



View larger version (90K):
[in this window]
[in a new window]
  		Figure 1. Mechanisms of action of GTN. GTN is metabolized to NO, which stimulates the synthesis of cGMP. In turn, cGMP reduces cytoplasmic Ca2+ by inhibiting inflow and stimulating mitochondrial uptake, causing relaxation of smooth muscle cells. The role of Ca2+-activated K+ currents is also being investigated; by inducing hyperpolarization of the cellular membrane, they might contribute to the limitation of Ca2+ entry in smooth muscle cells, and, in endothelial cells, they might inhibit ·O2- production.53 By promoting Ca2+ uptake, ATII can increase cytoplasmic Ca2+ and induce the Ca2+-dependent PDE1A1. This may lead to reduced cGMP and cGK activity, providing an elegant explanation for both nitrate tolerance and increased sensitivity to ATII. There is evidence supporting a redox sensitivity of all enzymes involved in these processes. PDE1A1 indicates phosphodiesterase 1A1; GTP, guanosine tri-phosphate; cGMP, cyclic guanosine monophosphate; and ATII, angiotensin II.

Augmented catabolism by PDEs has been proposed as a mechanism that leads to reduced bioavailability of cGMP in the setting of tolerance,41 and a recent report demonstrated that the activity of the PDE 1A1 is increased in rats treated with continuous GTN.42 This finding, as the authors suggest, is consistent with both reduced responses to NO-dependent vasodilators and increased responses to vasoconstrictors that augment intracellular Ca2+ concentrations, such as angiotensin II and norepinephrine (Figure 1).

The effect of GTN on NO signaling mechanisms and the possibility that a dysfunction might be caused by increased free radical production were also recently investigated.43 Despite an increased basal expression of its components, the activity of the sGC-cGK pathway was significantly blunted, as assessed by the assay of the vasodilator-stimulated phosphoprotein, a marker of cGK activity. Both in vitro and in vivo treatment with vitamin C prevented the dysfunction of these enzymatic pathways, confirming the role of increased ·O2- bioavailability in the development of end-organ tolerance.43 Different studies have now demonstrated that elevated concentrations of peroxynitrite44 and ·O2- alone45 inhibit sGC, possibly through oxidation of thiol groups in its catalytic site46 that seem to be critical for the direct activation of the enzyme by GTN.47 Finally, in the presence of an excess of ·O2- and/or peroxynitrite, the activity of ion channels involved in the regulation of Ca2+ and K+ currents (which are the final mediators of GTN-induced vasodilatation48) seems to be compromised.49,50 Taken together, these lines of evidence suggest the existence of a fundamental mechanism, based on increased ·O2- generation, that leads to several of the abnormalities observed in nitrate tolerance.

The Trigger Mechanism
Therapy with organic nitrates is associated with a complex series of responses that seem to mediate the phenomenon of tolerance in a multifactorial fashion. At the moment, the most convincing hypothesis suggests that therapy with organic nitrates, particularly GTN, is associated with increased ·O2- bioavailability. As was discussed, there seem to be multiple potential sources for this ·O2-. Importantly, the initial step in this mechanistic cascade remains to be determined, and at this time investigative efforts need to realize the primary trigger of this increase in free radical production. Increased ·O2- bioavailability might explain a number of the abnormalities described during nitrate therapy, including direct GTN-derived NO quenching, NOS uncoupling (and thus further reduced NO and increased ·O2- generation), increased production of potentially harmful mediators such as peroxynitrite and isoprostanes, increased sympathetic activity, and possibly also decreased end-organ effect and biotransformation of GTN. In light of this, a determination of the original trigger of this abnormal production remains a critical component of our understanding of these events.

Importantly, recent studies have demonstrated that ·O2- seems to be generated instantaneously on bolus GTN administration, suggesting that it might be a direct by-product of GTN biotransformation.51,52 It is possible that this initial increase in ·O2- could play a role as primary stimulus for a series of events that eventually lead to the development of both tolerance and endothelial dysfunction. Indeed, if ·O2- is released directly after GTN administration, increased peroxynitrite formation could result from the interaction between ·O2- and the NO released from GTN. This generation of ·O2- and peroxynitrite, intrinsic in the administration of GTN, might provoke a series of autocatalytic mechanisms leading to further redox unbalance (Figure 2) and, ultimately, tolerance.



View larger version (34K):
[in this window]
[in a new window]
  		Figure 2. Diagram describing the different mechanisms through which an initial increased production of oxidant free radicals might trigger a series of autocatalytic processes leading to further ·O2- and peroxynitrite generation. Superoxide anion and peroxynitrite may result in NOS uncoupling,19,40 sympathetic activation,40,58 SOD inhibition,59 and increased production and responsiveness to vasoconstrictors such as angiotensin II. These phenomena, in turn, might lead to further increases in oxidative stress. SOD indicates superoxide dismutase; ATII, angiotensin II; and ET-1, endothelin-1.

Perspectives
In conclusion, despite the fact that there continue to be many uncertainties, recent findings allow the formulation of a "unifying" hypothesis of nitrate tolerance that has its fundamental basis in an increased ·O2- production. More research is now necessary to further substantiate the redox sensitivity of GTN biotransformation, NO signal transduction, volume expansion, and other recently described pathways (eg, endothelial Ca2+-activated K+ channels53).

From the clinical point of view, many strategies have been used in an effort to prevent or modify nitrate tolerance. The failure of these strategies to produce a definitive solution has often been attributed to the multifactorial nature of this phenomenon. We believe that recent insights into the mechanism of tolerance have 2 important implications. First, the concept that many systemic and local abnormalities induced by GTN treatment might arise from a common origin would suggest that, once the original source of ·O2- is identified, a rational, targeted approach to the prevention of tolerance and nitrate-induced endothelial dysfunction could be developed. Second, the demonstration that organic nitrates can cause free radical production, endothelial dysfunction, and sympathetic activation would suggest that nitrate therapy may have long-term detrimental effects. Large-scale prospective studies of the use of nitrates in coronary artery disease were relatively short and produced controversial results.54,55 At the moment, one can only conclude that we have no hard data concerning the impact of long-term nitrate therapy on clinical outcome. GTN seems to increase matrix metalloproteinases activity (possibly rising the risk of plaque rupture56), and a recent meta-analysis of patients after a myocardial infarction showed increased risk of cardiac death in patients treated with organic nitrates.57 Therefore, in the absence of more definitive data, the knowledge that therapy with organic nitrates causes both increased ·O2- production and endothelial dysfunction places a cautionary note on the traditional assumptions about their beneficial effects.

Acknowledgments

Dr Gori is the recipient of a research fellowship from the Heart and Stroke Foundation of Ontario, Canada. Dr Parker is a Career Investigator of the same institution.

Footnotes

This article is the second part of a 2-part article. The first part appeared in the October 29, 2002, issue of the journal (Circulation. 2002;106:2510–2513).

References

  1. Munzel T, Kurz S, Heitzer T, et al. New insights into mechanisms underlying nitrate tolerance. Am J Cardiol. 1996; 77: 24C–30C.[CrossRef][Medline] [Order article via Infotrieve]
  2. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998; 338: 520–531.[Free Full Text]
  3. Packer M. What causes tolerance to nitroglycerin? The 100 year old mystery continues. J Am Coll Cardiol. 1990; 16: 932–935.[Medline] [Order article via Infotrieve]
  4. Armstrong PW, Moffat JA. Tolerance to organic nitrates: clinical and experimental perspectives. Am J Med. 1983; 74: 73–84.
  5. Parker JD, Farrell B, Fenton T, et al. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation. 1991; 84: 2336–2345.[Abstract/Free Full Text]
  6. Dupuis J, Lalonde G, Lemieux R, et al. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol. 1990; 16: 923–931.[Abstract]
  7. Parker JD. Counterregulatory responses: sustained-release isosorbide-5-mononitrate versus transdermal nitroglycerin. J Cardiovasc Pharmacol. 1996; 28: 631–638.[CrossRef][Medline] [Order article via Infotrieve]
  8. Jurt U, Gori T, Ravandi A, et al. Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study. J Am Coll Cardiol. 2001; 38: 854–859.[Abstract/Free Full Text]
  9. Romero JC, Reckelhoff JF. Oxidative stress may explain how hypertension is maintained by normal levels of angiotensin II. Braz J Med Biol Res. 2000; 33: 653–660.[Medline] [Order article via Infotrieve]
  10. Zhao X, Alexander JS, Zhang S, et al. Redox regulation of endothelial barrier integrity. Am J Physiol Lung Cell Mol Physiol. 2001; 281: L879–L886.[Abstract/Free Full Text]
  11. Parker JD, Farrell B, Fenton T, et al. Effects of diuretic therapy on the development of tolerance during continuous therapy with nitroglycerin. J Am Coll Cardiol. 1992; 20: 616–622.[Abstract]
  12. Parker JD, Parker AB, Farrell B, et al. Effects of diuretics therapy on the development of tolerance to nitroglycerin and exercise capacity in patients with chronic stable angina. Circulation. 1996; 93: 691–696.[Abstract/Free Full Text]
  13. Needleman P, Johnson EM Jr. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther. 1973; 184: 709–715.[Abstract/Free Full Text]
  14. Laursen JB, Mulsch A, Boesgaard S, et al. In vivo nitrate tolerance is not associated with reduced bioconversion of nitroglycerin to nitric oxide. Circulation. 1996; 94: 2241–2247.[Abstract/Free Full Text]
  15. Fung HL, Poliszczuk R. Nitrosothiol and nitrate tolerance. Z Kardiol. 1986; 75 (suppl 3): 25–27.[Medline] [Order article via Infotrieve]
  16. Sage PR, de LL, Stafford I, et al. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation. 2000; 102: 2810–2815.[Abstract/Free Full Text]
  17. Miller MR, Megson IL, Roseberry MJ, et al. Novel s-nitrosothiols do not engender vascular tolerance and remain effective in glyceryl trinitrate-tolerant rat femoral arteries. Eur J Pharmacol. 2000; 403: 111–119.[CrossRef][Medline] [Order article via Infotrieve]
  18. Sutsch G, Kim JH, Bracht C, et al. Lack of cross-tolerance to short-term linsidomine in forearm resistance vessels and dorsal hand veins in subjects with nitroglycerin tolerance. Clin Pharmacol Ther. 1997; 62: 538–545.[CrossRef][Medline] [Order article via Infotrieve]
  19. Gori T, Mak SS, Kelly S, et al. Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J Am Coll Cardiol. 2001; 38: 1096–1101.[Abstract/Free Full Text]
  20. Bohyn M, Berkenboom G, Fontaine J. Effect of nitrate tolerance and dipyridamole on the response to SIN1 in the human isolated saphenous vein. Cardiovasc Drugs Ther. 1991; 5: 457–461.[Medline] [Order article via Infotrieve]
  21. Mulsch A, Mordvintcev P, Bassenge E, et al. In vivo spin trapping of glyceryl trinitrate-derived nitric oxide in rabbit blood vessels and organs. Circulation. 1995; 92: 1876–1882.[Abstract/Free Full Text]
  22. Bredt DS, Hwang PM, Glatt CE, et al. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature. 1991; 351: 714–718.[CrossRef][Medline] [Order article via Infotrieve]
  23. McDonald BJ, Bennett BM. Cytochrome P-450 mediated biotransformation of organic nitrates. Can J Physiol Pharmacol. 1990; 68: 1552–1557.[Medline] [Order article via Infotrieve]
  24. Ratz JD, McGuire JJ, Anderson DJ, et al. Effects of the flavoprotein inhibitor, diphenyleneiodonium sulfate, on ex vivo organic nitrate tolerance in the rat. J Pharmacol Exp Ther. 2000; 293: 569–577.[Abstract/Free Full Text]
  25. Minamiyama Y, Imaoka S, Takemura S, et al. Escape from tolerance of organic nitrate by induction of cytochrome P450. Free Radic Biol Med. 2001; 31: 1498–1508.[CrossRef][Medline] [Order article via Infotrieve]
  26. Kojda G, Patzner M, Hacker A, et al. Nitric oxide inhibits vascular bioactivation of glyceryl trinitrate: a novel mechanism to explain preferential venodilation of organic nitrates. Mol Pharmacol. 1998; 53: 547–554.[Abstract/Free Full Text]
  27. Needleman P, Jakschik B, Johnson EM Jr. Sulfhydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exp Ther. 1973; 187: 324–331.[Abstract/Free Full Text]
  28. Boesgaard S, Aldershvile J, Poulsen HE, et al. Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ Res. 1994; 74: 115–120.[Abstract/Free Full Text]
  29. Hofmann H, Schmidt HH. Thiol dependence of nitric oxide synthase. Biochemistry. 1995; 34: 13443–13452.[CrossRef][Medline] [Order article via Infotrieve]
  30. Seth P, Fung HL. Biochemical characterization of a membrane-bound enzyme responsible for generating nitric oxide from nitroglycerin in vascular smooth muscle cells. Biochem Pharmacol. 1993; 46: 1481–1486.[CrossRef][Medline] [Order article via Infotrieve]
  31. Daiber A, Herold S, Schoneich C, et al. Nitration and inactivation of cytochrome P450BM-3 by peroxynitrite. stopped-flow measurements prove ferryl intermediates. Eur J Biochem. 2000; 267: 6729–6739.[Medline] [Order article via Infotrieve]
  32. Mehl M, Daiber A, Herold S, et al. Peroxynitrite reaction with heme proteins. Nitric Oxide. 1999; 3: 142–152.[CrossRef][Medline] [Order article via Infotrieve]
  33. Wong PS, Eiserich JP, Reddy S, et al. Inactivation of glutathione s-transferases by nitric oxide-derived oxidants: exploring a role for tyrosine nitration. Arch Biochem Biophys. 2001; 394: 216–228.[CrossRef][Medline] [Order article via Infotrieve]
  34. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA. 2002; 99: 8306–8311.[Abstract/Free Full Text]
  35. Brown GC. Nitric oxide and mitochondrial respiration. Biochim Biophys Acta. 1999; 1411: 351–369.[Medline] [Order article via Infotrieve]
  36. Molina CR, Andresen JW, Rapoport RM, et al. Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta. J Cardiovasc Pharmacol. 1987; 10: 371–378.[Medline] [Order article via Infotrieve]
  37. Kowaluk EA, Fung HL. Dissociation of nitrovasodilator-induced relaxation from cyclic GMP levels during in vitro nitrate tolerance. Eur J Pharmacol. 1990; 176: 91–95.[CrossRef][Medline] [Order article via Infotrieve]
  38. Soff GA, Cornwell TL, Cundiff DL, et al. Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP. J Clin Invest. 1997; 100: 2580–2587.[Medline] [Order article via Infotrieve]
  39. Ratz JD, McGuire JJ, Anderson DJ, et al. Effects of the flavoprotein inhibitor, diphenyleneiodonium sulfate, on ex vivo organic nitrate tolerance in the rat. J Pharmacol Exp Ther. 2000; 293: 569–577.[Abstract/Free Full Text]
  40. Munzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995; 95: 187–194.[Medline] [Order article via Infotrieve]
  41. Axelsson KL, Ahlner J. Nitrate tolerance from a biochemical point of view. Drugs. 1987; 33 (suppl 4): 63–68.[Medline] [Order article via Infotrieve]
  42. Kim D, Rybalkin SD, Pi X, et al. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation. 2001; 104: 2338–2343.[Abstract/Free Full Text]
  43. Mulsch A, Oelze M, Kloss S, et al. Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation. 2001; 103: 2188–2194.[Abstract/Free Full Text]
  44. Weber M, Lauer N, Mulsch A, et al. The effect of peroxynitrite on the catalytic activity of soluble guanylyl cyclase. Free Radic Biol Med. 2001; 31: 1360–1367.[CrossRef][Medline] [Order article via Infotrieve]
  45. Guthrie F. Contributions to the knowledge of the amyl group. J Chem Soc. 1859; 11: 245–252.
  46. Kamisaki Y, Waldman SA, Murad F. The involvement of catalytic site thiol groups in the activation of soluble guanylate cyclase by sodium nitroprusside. Arch Biochem Biophys. 1986; 251: 709–714.[CrossRef][Medline] [Order article via Infotrieve]
  47. Artz JD, Schmidt B, McCracken JL, et al. Effects of nitroglycerin on soluble guanylate cyclase: implications for nitrate tolerance. J Biol Chem. 2002; 277: 18253–18256.[Abstract/Free Full Text]
  48. Khan SA, Higdon NR, Meisheri KD. Coronary vasorelaxation by nitroglycerin: involvement of plasmalemmal calcium-activated K+ channels and intracellular Ca++ stores. J Pharmacol Exp Ther. 1998; 284: 838–846.[Abstract/Free Full Text]
  49. Liu Y, Gutterman DD. Oxidative stress and potassium channel function. Clin Exp Pharmacol Physiol. 2002; 29: 305–311.[CrossRef][Medline] [Order article via Infotrieve]
  50. Grover AK, Samson SE. Effect of superoxide radical on Ca2+ pumps of coronary artery. Am J Physiol. 1988; 255(pt 1): C297–C303.
  51. Fink B, Dikalov S, Bassenge E. A new approach for extracellular spin trapping of nitroglycerin-induced superoxide radicals both in vitro and in vivo. Free Radic Biol Med. 2000; 28: 121–128.[CrossRef][Medline] [Order article via Infotrieve]
  52. Dikalov S, Fink B, Skatchkov M, et al. Formation of reactive oxygen species in various vascular cells during glyceryltrinitrate metabolism. J Cardiovasc Pharmacol Ther. 1998; 3: 51–62.[Abstract/Free Full Text]
  53. Gruhn N, Boesgaard S, Eiberg J, et al. Effects of large conductance Ca(2+)-activated K(+) channels on nitroglycerin-mediated vasorelaxation in humans. Eur J Pharmacol. 2002; 446: 145–150.[CrossRef][Medline] [Order article via Infotrieve]
  54. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet. 1994; 343: 1115–1120.[Medline] [Order article via Infotrieve]
  55. ISIS-4. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995; 345: 669–685.[CrossRef][Medline] [Order article via Infotrieve]
  56. Death AK, Nakhla S, McGrath KC, et al. Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages. J Am Coll Cardiol. 2002; 39: 1943–1950.[Abstract/Free Full Text]
  57. Nakamura Y, Moss AJ, Brown MWY, et al. Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J. 1999; 138(pt 1): 577–585.
  58. Zanzinger J, Czachurski J, Seller H. Impaired modulation of sympathetic excitability by nitric oxide after long-term administration of organic nitrates in pigs. Circulation. 1998; 97: 2352–2358.[Abstract/Free Full Text]
  59. MacMillan-Crow LA, Crow JP, Thompson JA. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry. 1998; 37: 1613–1622.[CrossRef][Medline] [Order article via Infotrieve]



This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
T. Gori and J. D. Parker
Nitrate-Induced Toxicity and Preconditioning: A Rationale for Reconsidering the Use of These Drugs
J. Am. Coll. Cardiol., July 22, 2008; 52(4): 251 - 254.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
A. Daiber and T. Gori
Vascular tolerance to nitroglycerin in ascorbate deficiency: results are in favour of an important role of oxidative stress in nitrate tolerance
Cardiovasc Res, July 9, 2008; (2008) cvn174v2.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. R. Thomas, J. M. DiFabio, T. Gori, and J. D. Parker
Once Daily Therapy With Isosorbide-5-Mononitrate Causes Endothelial Dysfunction in Humans: Evidence of a Free-Radical-Mediated Mechanism
J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1289 - 1295.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. M. DiFabio, G. R. Thomas, L. Zucco, M. A. Kuliszewski, B. M. Bennett, M. J. Kutryk, and J. D. Parker
Nitroglycerin Attenuates Human Endothelial Progenitor Cell Differentiation, Function, and Survival
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 117 - 123.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. D. MacPherson, T. D. Gillespie, H. A. Dunkerley, D. H. Maurice, and B. M. Bennett
Inhibition of Phosphodiesterase 5 Selectively Reverses Nitrate Tolerance in the Venous Circulation
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 188 - 195.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
R. Parent, N. Leblanc, and M. Lavallee
Nitroglycerin reduces myocardial oxygen consumption during exercise despite vascular tolerance
Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1226 - H1234.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
L. Tavazzi
The need to identify new targets for therapeutic intervention in angina
Eur. Heart J. Suppl., February 1, 2006; 8(suppl_A): A3 - A5.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. Abrams
Chronic Stable Angina
N. Engl. J. Med., June 16, 2005; 352(24): 2524 - 2533.
[Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
U. Elkayam, F. Bitar, M. W. Akhter, S. Khan, S. Patrus, and M. Derakhshani
Intravenous Nitroglycerin in the Treatment of Decompensated Heart Failure: Potential Benefits and Limitations
Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2004; 9(4): 227 - 241.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
T. Gori and J. D. Parker
Long-term therapy with organic nitrates: The pros and cons of nitric oxide replacement therapy
J. Am. Coll. Cardiol., August 4, 2004; 44(3): 632 - 634.
[Full Text] [PDF]

Home page
 CirculationHome page
F. Mullershausen, M. Russwurm, A. Friebe, and D. Koesling
Inhibition of Phosphodiesterase Type 5 by the Activator of Nitric Oxide-Sensitive Guanylyl Cyclase BAY 41-2272
Circulation, April 13, 2004; 109(14): 1711 - 1713.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
H. J. Knot
Nitrate Tolerance in Hypertension: New Insight Into a Century-Old Problem
Circ. Res., October 31, 2003; 93(9): 799 - 801.
[Full Text] [PDF]

Home page
 Circ. Res.Home page
A. L. Kleschyov, M. Oelze, A. Daiber, Y. Huang, H. Mollnau, E. Schulz, K. Sydow, B. Fichtlscherer, A. Mulsch, and T. Munzel
Does Nitric Oxide Mediate the Vasodilator Activity of Nitroglycerin?
Circ. Res., October 31, 2003; 93 (9): e104 - e112.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. D. Horowitz
Amelioration of nitrate tolerance: matching strategies with mechanisms
J. Am. Coll. Cardiol., June 4, 2003; 41(11): 2001 - 2003.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. J. Oliver and D. J. Webb
Noninvasive Assessment of Arterial Stiffness and Risk of Atherosclerotic Events
Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 554 - 566.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gori, T.
Right arrow Articles by Parker, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gori, T.
Right arrow Articles by Parker, J. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Endothelium/vascular type/nitric oxide

Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.